जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

nipro corporation - azilsartan - faintly yellowish red tablet, major axis: 8.2 mm, minor axis: 4.7 mm, thickness: approx. 3.1 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

sandoz k.k. - azilsartan - faintly yellowish red tablet, major axis: 7.3 mm, minor axis: 4.2 mm, thickness: approx. 3.2 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - azilsartan - pale yellowish red tablet, diameter: 6.6 mm, thickness: 3.4 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

nipro corporation - azilsartan - faintly red tablet, major axis: 9.1 mm, minor axis: 5.1 mm, thickness: approx. 3.3 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

sandoz k.k. - azilsartan - faintly red tablet, major axis: 9.2 mm, minor axis: 5.2 mm, thickness: approx. 3.3 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - azilsartan - faint red tablet, major axis: 10.1 mm, minor axis: 4.6 mm, thickness: 3.6 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

nipro corporation - azilsartan - yellow tablet, major axis: 9.1 mm, minor axis: 5.1 mm, thickness: approx. 3.3 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

sandoz k.k. - azilsartan - yellow tablet, major axis: 9.2 mm, minor axis: 5.2 mm, thickness: approx. 3.3 mm

जापान - अंग्रेज़ी - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - azilsartan - pale yellow tablet, major axis: 10.1 mm, minor axis: 4.6 mm, thickness: 3.6 mm

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sanof-aventis u.s. llc - isatuximab (unii: r30772kcu0) (isatuximab - unii:r30772kcu0) - sarclisa is indicated: - in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. - in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. sarclisa is contraindicated in patients with severe hypersensitivity to isatuximab-irfc or to any of its excipients [see warnings and precautions (5.1)] . risk summary sarclisa can cause fetal harm when administered to a pregnant woman. the assessment of isatuximab-irfc-associated risks is based on the mechanism of action and data from target antigen cd38 knockout animal models (see data). there are no available data on sarclisa use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction toxicity studies hav